BMG SKI-606 Bosutinib ofatumumabmg Octoberto or April. One patient in group withdrew before the start of treatment themg and was excluded from the analysis. The median age of patients wasyears andyears for themg andmg dose group. Seventy percent of patients had six andof intermedi Rem-risk or high-risk scores Flipi themg andmg groups, respectively, the patients had Ann Arbor stage andandof iiiiv disease. All patients in both groups had baseline dose H Hemoglobin less thangl. Twenty-seven of andpatients themg andmg dose groups and completed all six cycles of treatment. Two withdrawals occurred themg group was withdrawn in a patient because of an AE and a patient because of the St Tion, a PR after three cycles of treatment was withdrawn to achieve. Before infusion, patients were re-sand U Pr Medication stero Compliance with the study protocol.
Pr Medication stero Was given at the discretion of the attending physician, infusion-sand Toof patients prior to infusion, patients patients infusionandof before. The most hours Ufigsten reported infections were undesirable. Of these, a third year of infection was reported and considered unrelated to study medication. Some patients had a total of ofof infections that were considered related to treatment and all were gradeor ofatumumab. Respiratory diseases are the hours Ufigsten infectious adverse events reported See Sechsunddrei Ig percent of patients experienced adverse effects gradeorhaematological, most of which were not attributed to ofatumumab of investigators were neutropenia and leukopenia, the h Most frequent.
Through laboratory tests, leukopenia and neutropenia, which h H were most frequent Dermatological toxicity Nth degree. No Todesf ll Were reported. Ofatumumab CD publ fast Pft peripheral blood B cells and CD. Median lymphocyte CD and CD decreased fromand l at the beginning of the study, the atandmonths after treatment with ofatumumab. Recovery of circulating B cells after treatment beganmonths ofatumumab. Pharmacokinetics The pharmacokinetic data were available at least months after the last dose in most patients. Maximum concentration observed ofatumumab and minimum concentration values of n before Chsten infusion increases with repeated dosing. W During the sixth infusion, values of the geometric mean distance And MLH, volume of distribution at steady values were And L, and the values of the half-life were And Groups in each theandmg doses.
C max, C min and AUC values of concentration in time themg dose group were approximately twice as high as the themg dose group. Discussion The results of this study showed that ofatumumab plus CHOP is a very active system for previously untreated patients with FL, and the realization of Verg tungss Tze CRCRu ofand or is. O CHOP was effective in all risk groups, reaching a speed Flipi Ofin CRCRu patients at high risk, with hints of Flipi. There were no clinically significant differences in overall response, CR or CRCRu rates between the two treatment groups. This is consistent with the results above withandmg of ofatumumab monotherapy in patients with rituximab refractory- Rem FL described. Since there was no increase in toxicity T when comparing dose group with themg dose group was themg themg dose for further studies in combination with weight Chemother Hlt